In another randomized phase 2 study, a combination of temsirolimus and cetuximab induced a significantly high response in cetuximab-resistant R/M-HNSCC patients compared with temsirolimus alone, although no significant improvement in PFS was observed, indicating that dual blockade of mTOR and EGFR pathways may be a potential strategy to overcome EGFR resistance.501. Here, MTOR is linked to head and neck squamous cell carcinoma.